Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 3/20 | 0.53 |
| ▸ | CDK8 | P49336 | 3/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA4 | P22748 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518895 | 0.88 | EPHX2 (0.54) | CCNCCDK8PDGFRBCA12CA1 | |
| SCHEMBL14599436 | 0.84 | PDGFRB (0.49) | PDGFRBALDH1A1 | |
| SCHEMBL14599437 | 0.82 | PDGFRB (0.53) | PDGFRBALDH1A1 | |
| SCHEMBL14515649 | 0.78 | SMPD3 (0.50) | AKT1 | |
| SCHEMBL14599468 | 0.77 | EPHX2 (0.48) | CCNCCDK8EPHX2 | |
| SCHEMBL4970207 | 0.77 | PDGFRB (0.67) | PDGFRB | |
| SCHEMBL4199286 | 0.76 | PAK1 (0.50) | CCNCCDK8PDGFRBAKT1 | |
| SCHEMBL4200992 | 0.76 | CCNC (0.48) | CCNCCDK8PDGFRBAKT1 | |
| SCHEMBL4969355 | 0.75 | AKT1 (0.54) | PDGFRBEPHX2AKT1 | |
| SCHEMBL4969148 | 0.75 | PDE10A (0.57) | PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, CDC42BPG, PRKCQ | CCNC 454/4885CDK8 962/4885PDGFRB 284/4885 |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, BMX, ABL1 | CCNC 249/4885CDK8 464/4885PDGFRB 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.